NASDAQ: KYMR

Kymera Therapeutics (KYMR) Stock Analysis & Forecast

Nov 13 close

$127.57+0.40 (+0.3%)

Gekko Brief

AI summaryNov 9 close

Kymera Therapeutics moves this week on Q3 2026 results, which showed a net loss of $132 million as the company prioritizes pipeline progress for protein degradation candidates KT-579 and KT-621 over near-term profitability, alongside an EPS of -$1.32 that missed estimates by $0.05. Shares touched an all-time high of $130.48 before falling 5.97% on 5 November to close at $128.12, then recovering into the latest close. Barclays maintained its Overweight rating and raised its price target to $170 from $139, citing continued confidence in the clinical-stage story.

The stock closes at $138.86, up 5.4%, sitting above both its 50-day average of $116.08 and 200-day average of $98.26, with the 50-day above the 200-day in a supportive trend structure. The GekkoIndex reads 43, placing it in the Distribution zone. Price sits 18.7% above Gekko Fair Value of $116.98, a notable premium to that benchmark.

The next earnings date falls on 25 February 2027, 107 days out and beyond a typical 20-trading-day holding window. Seasonality over the next 20 trading days has averaged a 12.7% return across 5 years, though gains occurred in only 2 of those years. Smart money activity shows no insider, Congress or unusual options signals in their respective windows. Analyst sentiment remains heavily tilted toward buy ratings, with a consensus target of $144.57.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Kymera Therapeutics price vs fair value

$127.57$117.93Nov ’25May ’26Nov ’26
Close $127.57200-day averageGekko Fair Value $117.93

Kymera Therapeutics quick facts

Market cap
$10.89B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$3.64
Revenue, TTM
$102.2M
Profit margin
0%
Dividend yield
—
Beta
2.03
Volume
808,708 avg 974,294
1-year return
+100.8%
Typical daily move
±6.3%
Typical 20-day move
±11.9%
50-day average
$117.13
200-day average
$99.45
Next earnings
Feb 25 before open
Shares outstanding
85.37M
52-week range
$61.50$142.92

Kymera Therapeutics swing-trade checklist

Kymera Therapeutics scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $127.57 is above the 50-day ($117.13) and 200-day ($99.45) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.7, Neutral

    Reading 53.7 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    8.2% above

    Price is 8.2% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +7.0% on average

    From this point in the calendar, the next 20 trading days averaged +7% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Kymera Therapeutics stock chart and price history

Kymera Therapeutics closed at $127.57 on Nov 13, 2026, +100.8% over the past year, inside a 52-week range of $61.50 to $142.92.

Close50-day average200-day averageVolume
Kymera Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$40$60$80$100$120$140DecJan 2026FebMarAprMayJunJulAugSepOctNov127.57

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+18.0%
3 months
+5.1%
6 months
+55.2%
1 year
+100.8%
The full KYMR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KYMR in Gekko

Follow Kymera Therapeutics through every session

Put KYMR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track KYMR in GekkoFree for 7 days. No credit card required.

About Kymera Therapeutics

Kymera Therapeutics is a biopharmaceutical business focused on building small molecule drugs that tap into a natural cellular process for clearing proteins tied to illness. Rather than blocking disease proteins, its compounds are designed to flag them for removal using pathways the body already has, and this degradation-based approach is the throughline across its research efforts and candidate therapies.

The company runs several drug programs aimed at different conditions. One candidate, targeting IRAK4, has reached Phase I testing and is being explored for conditions such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, generalized pustular psoriasis, and macrophage activation syndrome. A separate effort, IRAKIMiD, is being developed for a form of diffuse large B cell lymphoma linked to MYD88 mutations. The STAT3 program looks at blood cancers, solid tumors, fibrosis, and autoimmune conditions, while a fourth program centered on MDM2 is also being pursued for blood cancers and solid tumors.

Kymera Therapeutics traces its founding to 2015 and operates out of Watertown, Massachusetts. Its stock trades on the NASDAQ exchange under the symbol KYMR.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
kymeratx.com

Kymera Therapeutics GekkoIndex: the smart money zone

Kymera Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.7, in the Neutral zone, up 8.5 points over five sessions.

010053.7Neutral

Up 8.5 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying23+6.4%+18.0%+24.6%+57.1%
Accumulation208+1.9%+4.3%+7.7%+12.6%
Neutral (current zone)396+0.9%+1.1%+3.2%+10.4%
Distribution71+2.8%+4.9%+4.7%+4.8%
Selling4Too few readings yet

Average KYMR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the KYMR price, zone by zone.Track KYMR in Gekko

Is Kymera Therapeutics stock overvalued? Gekko Fair Value

Kymera Therapeutics trades 8.2% above Gekko Fair Value of $117.93, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Kymera Therapeutics shares are worth, recalculated every trading day.

$117.93

Gekko Fair Value, Nov 14, 2026

8.2% Overvalued

At the end of Aug 2026 the price was 5.4% below the estimate.

Gekko Fair ValueShare price, month end
$118$128Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open KYMR in Gekko

Kymera Therapeutics insider and Congress trading

No open-market insider purchases were filed for Kymera Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for KYMR in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every KYMR insider filing, plotted on the chart in Gekko.Open KYMR in Gekko

Congress trades last 90 days

No trades in KYMR were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for KYMR, plotted on the chart in Gekko.Open KYMR in Gekko

Unusual options activity last 30 days

1signal, 83% of the flagged premium in calls.

Latest: Bullish flow on Nov 10, $3.62M in unusual premium.

Hedge funds and billionaires quarter ended Mar 31

0of the funds Gekko tracks hold KYMR.

0added0opened0trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Kymera Therapeutics earnings: next date and track record

Kymera Therapeutics reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±3%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−2.5%Oct ’24−11.3%Feb ’25+4.5%May ’25−1.8%Aug ’25+0.3%Nov ’25+0.7%Feb ’26−1.0%Apr ’26+1.9%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Kymera Therapeutics reported strong Q2 2026 momentum highlighted by completing enrollment in their Phase 2b atopic dermatitis (AD) trial approximately 6 months ahead of schedule. The company is advancing their STAT6 program alongside a broader pipeline leveraging targeted protein degradation and small molecule capabilities. A leadership transition is underway with CMO Jared Gollob retiring and Terence Rooney stepping into the role.
Guidance
Kymera now expects Phase 2b AD trial top-line data by year-end 2026 and Phase 3 initiation around mid-2027, both approximately 6 months earlier than previously planned due to accelerated enrollment completion.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026−$0.62
est −$0.64
+3.1%$65.00M
est $32.78M
+98.3%+1.9%
Apr 30, 2026−$0.71
est −$0.86
+17.4%$34.37M
est $8.27M
+315.7%−1.0%
Feb 26, 2026−$0.97
est −$0.78
−23.8%$2.87M
est $15.05M
−80.9%+0.7%
Nov 4, 2025−$0.90
est −$0.71
−26.8%$2.76M
est $14.45M
−80.9%+0.3%
Aug 11, 2025−$0.95
est −$0.83
−14.5%$11.48M
est $17.13M
−33.0%−1.8%
May 9, 2025−$0.82
est −$0.92
+10.9%$22.10M
est $12.38M
+78.5%+4.5%
Feb 27, 2025−$0.88
est −$0.76
−15.8%$7.39M
est $16.68M
−55.7%−11.3%
Oct 31, 2024−$0.82
est −$0.83
+1.2%$3.74M
est $15.21M
−75.4%−2.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Kymera Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Kymera Therapeutics is $145.22, +13.8% from the last close, from 15 firms rating the stock in the last 90 days.

$145.22consensus 12-month target, +13.8% from the last close
Low $116High $180
Buy14
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 15 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 3Canaccord GenuityBuy, reiterated$129+1.1%
Nov 2BarclaysBuy, maintained$170+33.3%
Nov 2Leerink PartnersBuy, maintained$140+9.7%
Nov 1BTIGBuy, maintained$139+9.0%
Oct 30Morgan StanleyBuy, maintained$150+17.6%
+3.2%average 20-day move after past Neutral readings
+7.0%average move over the next 20 trading days in the last 5 years
±6.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Kymera Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Kymera Therapeutics averaged +7.0% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−12.7%2021−10.9%2022+40.2%2023−8.3%2024+31.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.0%2 of 5
Next 10 trading days+0.2%2 of 5
Next 15 trading days+9.5%2 of 5
Next 20 trading days+7.0%2 of 5
Next 30 trading days+8.9%3 of 5

For scale, KYMR’s typical 20-trading-day move in either direction is about 11.9%.

Kymera Therapeutics market cap and key statistics

Kymera Therapeutics’s market cap is $10.89B and revenue of $102.2M over the last twelve months.

Valuation

Market cap
$10.89B
EPS, TTM
−$3.64
Gekko Fair Value
$117.93

Trading

Volume
808,708
Avg volume, 20 days
974,294
52-week high
$142.92
52-week low
$61.50
Shares outstanding
85.37M

Financials

Revenue, TTM
$102.2M
Profit margin
0%
Return on equity
-27.3%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
2.03
Typical daily move
±6.3%
Typical 20-day move
±11.9%

Kymera Therapeutics stock news this week

Coverage of Kymera Therapeutics this week reads neutral: 1 positive, 4 neutral and 0 negative headlines.

News sentiment neutral

Kymera Therapeutics peers

Kymera Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Kymera Therapeutics stock FAQ

What is Kymera Therapeutics’s market cap?

Kymera Therapeutics’s market cap is $10.89B at the Nov 13, 2026 close of $127.57, with 85.37M shares outstanding.

What is the Kymera Therapeutics stock forecast?

The consensus analyst 12-month price target for Kymera Therapeutics is $145.22, +13.8% from the last close. Of the 15 firms that rated the stock in the last 90 days, 14 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Kymera Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Kymera Therapeutics is overvalued: the Nov 13, 2026 close of $127.57 is 8.2% above Gekko Fair Value of $117.93. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Kymera Therapeutics report earnings next?

Kymera Therapeutics is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of −$1.29 per share on revenue of $253K. Kymera Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 3% on average across the report.

What is Kymera Therapeutics’s 52-week high and low?

Kymera Therapeutics’s 52-week high is $142.92 and its 52-week low is $61.50; it closed at $127.57 on Nov 13, 2026, +100.8% over the past year.

Is Kymera Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Kymera Therapeutics?

Gekko flagged 1 unusual options signal in Kymera Therapeutics over the last 30 days, with $3.00M of flagged premium in calls and $625K in puts. The latest, bullish flow, was on Nov 10, 2026 with $3.62M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Kymera Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.